Inositol safety: Clinical evidences

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 8, 2011, Pages 931-936

  Carlomagno, Gianfranco ^a   Unfer, V ^a  

^a AGUNCO Obstetrics and Gynecology Centre   (Italy)

Author keywords

Dosage; Myo inositol; NTDs; PCOS; Side effects

Indexed keywords

INOSITOL;

CARCINOGENESIS; CLINICAL STUDY; DIARRHEA; FLATULENCE; NAUSEA; NONHUMAN; REVIEW; ANIMAL; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG SCREENING; HUMAN; METHODOLOGY; STATISTICS;

ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; INOSITOL;

EID: 80052390793     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. LARNER J. D-chiro-inositol¬-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3: 47-60.
2. BLOOMGARDEN ZT, FUTTERWEIT W, PORETSKY L. Use of insulin-sensitizing agents in patients with polycystic ovary syndrome. Endocr Pract 2001; 7: 279-286.
3. COLONE M, MARELLI G, UNFER V, BOZZUTO G, MOLINARI A, STRINGARO A. Inositol activity in oligoasthenoteratospermia-an in vitro study. Eur Rev Med Pharmacol Sci 2010; 14: 891-896.
4. GERLI S, PAPALEO E, FERRARI A, DI RENZO GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007; 11: 347-354.
5. PAPALEO E, UNFER V, BAILLARGEON JP, DE SANTIS L, FUSI F, BRIGANTE C, MARELLI G, CINO I, REDAELLI A, FERRARI A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700-703.
6. PAPALEO E, UNFER V, BAILLARGEON JP, FUSI F, OCCHI F, DE SANTIS L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91: 1750-1754.
7. GENAZZANI AD, LANZONI C, RICCHIERI F, JASONNI VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 139-144.
8. MINOZZI M, D'ANDREA G, UNFER V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008; 17: 579-582.
9. CAVALLI P, COPP AJ. Inositol and folate resistant neural tube defects. J Med Genet 2002; 39: E5.
10. CAVALLI P, TEDOLDI S, RIBOLI B. Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs. Birth Defects Res A Clin Mol Teratol 2008; 82: 540-542.
11. PUGLIESE G, TILTON RG, SPEEDY A, SANTARELLI E, EADES DM, PROVINCE MA, KILO C, SHERMAN WR, WILLIAMSON JR. Modulation of hemodynamic and vascular filtration changes in diabetic rats by dietary myo-inositol. Diabetes 1990; 39: 312-322.
12. COPPEY LJ, GELLETT JS, DAVIDSON EP, DUNLAP JA, YOREK MA. Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Int J Exp Diabetes Res 2002; 3: 21-36.
13. VUCENIK I, SHAMSUDDIN AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003; 133: 3778S-3784S.
14. KASSIE F, MATISE I, NEGIA M, LAHTI D, PAN Y, SCHERBER R, UPADHYAYA P, HECHT SS. Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-inositol inhibit tobacco carcinogen-induced lung adenocarcinoma in mice. Cancer Prev Res (Phila) 2008; 1: 285-297.
15. KASSIE F, MELKAMU T, ENDALEW A, UPADHYAYA P, LUO X, HECHT SS. Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-1-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. Carcinogenesis 2010; 31: 1634-1641.
16. KASSIE F, KALSCHEUER S, MATISE I, MA L, MELKAMU T, UPADHYAYA P, HECHT SS. Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis 2010; 31: 239-245.
17. SOLOMONIA R, MIKAUTADZE E, NOZADZE M, KUCHIASHVILI N, LEPSVERIDZE E, KIGURADZE T. Myo-inositol treatment prevents biochemical changes triggered by kainate-induced status epilepticus. Neurosci Lett 2010; 468: 277-281.
18. LIAO J, SERIL DN, YANG AL, LU GG, YANG GY. Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. Carcinogenesis 2007; 28: 446-454.
19. TILTON RG, FALLER AM, LAROSE LS, BURGAN J, WILLIAMSON JR. Dietary myo-inositol supplementation does not prevent retinal and glomerular vascular structural changes in chronically diabetic rats. J Diabetes Complications 1993; 7: 188-198.
20. COSTANTINO D, MINOZZI G, MINOZZI E, GUARALDI C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009; 13: 105-110.
21. RIZZO P, RAFFONE E, BENEDETTO V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci 2010; 14: 555-561.
22. AGOSTINI R, ROSSI F, PAJALICH R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study. Eur Rev Med Pharmacol Sci 2006; 10: 247-250.
23. BARAK Y, LEVINE J, GLASMAN A, ELIZUR A, BELMAKER RH. Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 729-735.
24. ALLAN SJ, KAVANAGH GM, HERD RM, SAVIN JA. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. Br J Dermatol 2004; 150: 966-969.
25. LEVINE J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 1997; 7: 147-155.
26. BENJAMIN J, LEVINE J, FUX M, AVIV A, LEVY D, BELMAKER RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995; 152: 1084-1086.
27. PALATNIK A, FROLOV K, FUX M, BENJAMIN J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001; 21: 335-339.
28. GELBER D, LEVINE J, BELMAKER RH. Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord 2001; 29: 345-348.
29. FUX M, LEVINE J, AVIV A, BELMAKER RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996; 153: 1219-1221.
30. LEVINE J, KURTZMAN L, RAPOPORT A, ZIMMERMAN J, BERSUDSKY Y, SHAPIRO J, BELMAKER RH, AGAM G. CSF inositol does not predict antidepressant response to inositol. Short communication. J Neural Transm 1996; 103: 1457-1462.
31. LAM S, MCWILLIAMS A, LERICHE J, MACAULAY C, WATTENBERG L, SZABO E. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006; 15: 1526-1531.